Difference between revisions of "Team:CGU Taiwan"

 
(139 intermediate revisions by 2 users not shown)
Line 29: Line 29:
 
   height: 115px;
 
   height: 115px;
 
   font-family: Corbel;
 
   font-family: Corbel;
−
  background: rgba(250, 250, 250, 0.1);
 
 
   overflow: visible;
 
   overflow: visible;
 
   z-index: +1;
 
   z-index: +1;
Line 56: Line 55:
 
.header-subnav {
 
.header-subnav {
 
   float: none;
 
   float: none;
−
   background: rgba(250, 250, 250, 0.1);
+
   background: #0D014D;
 
   position: absolute;
 
   position: absolute;
 
   text-align: center;
 
   text-align: center;
Line 99: Line 98:
 
   left: 0px;
 
   left: 0px;
 
   width: 100%;
 
   width: 100%;
−
   height: 40%;
+
   height: 30%;
 
   font-family: Corbel;
 
   font-family: Corbel;
 
}
 
}
Line 113: Line 112:
 
   position: absolute;
 
   position: absolute;
 
   width: 100%;
 
   width: 100%;
−
   height: 40%;
+
   height: 35%;
 
   font-family: Corbel;
 
   font-family: Corbel;
 
}
 
}
Line 120: Line 119:
 
   position: absolute;
 
   position: absolute;
 
   width: 20%;
 
   width: 20%;
−
   height: 40%;
+
   height: 35%;
 
   font-family: Corbel;
 
   font-family: Corbel;
 
}
 
}
Line 128: Line 127:
 
   background-repeat:no-repeat;  
 
   background-repeat:no-repeat;  
 
   background-position:10px;  
 
   background-position:10px;  
−
   background-size:9.5%;
+
   background-size:9%;
 +
  margin-bottom:-20%;
 +
}
 +
.list2 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/2/2f/CGU_Taiwan--sitemap2.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:6px;
 +
  background-size:7%;
 +
  margin-bottom:-10%;
 +
}
 +
.list3 li {
 +
  list-style:none;
 +
  background-image:url(https://static.igem.org/mediawiki/2016/3/31/CGU_Taiwan--sitemap3.jpg);
 +
  background-repeat:no-repeat;
 +
  background-position:5%;
 +
  background-size:2%;
 +
  margin-bottom:-10%;
 
}
 
}
 
</style>
 
</style>
Line 151: Line 167:
  
 
<body>
 
<body>
−
<div class="top"><img style="margin-top:0px;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0a/CGU_Taiwan--home.jpg">
+
<a name='anchor1'></a>
 +
<div class="top">
 +
<img style="margin-top:-2%;width:100%;height:140%;position:absolute;" src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--top.jpg">
 
</div>
 
</div>
  
Line 167: Line 185:
 
   </div>
 
   </div>
 
</header>
 
</header>
−
 
+
<br><br><br>
 
<div>
 
<div>
−
<video width="100%" height="700px" controls  autoplay>
+
<br><br><br><br>
−
<source src="https://static.igem.org/mediawiki/2016/0/0b/CGU_Taiwan--videohome.mp4" type="video/mp4">
+
<video margin-top="5%" width="100%" height="700px" controls  autoplay>
 +
<source src="https://static.igem.org/mediawiki/2016/4/41/CGU_Taiwan--video4.mp4" type="video/mp4">
 
</video>
 
</video>
 
</div>
 
</div>
Line 177: Line 196:
 
<div class="mid">
 
<div class="mid">
 
<div style="font-size:60px;color:#140731;text-decoration:none;margin-left:45%;">
 
<div style="font-size:60px;color:#140731;text-decoration:none;margin-left:45%;">
 +
<br><br><br><br>
 
Abstract
 
Abstract
 
</div>
 
</div>
 
<br></br>
 
<br></br>
 
<br></br>
 
<br></br>
−
<b style="color:black;font-size:20px;margin-left:10%;">Leijuvant- A Revolutionary Choice of Vaccine Helper</b>
+
<b style="color:black;font-size:25px;margin-left:10%;">Leijuvant- A Revolutionary Choice of Vaccine Helper</b><br><br>
 
<div style="color:black;font-size:18px;margin-left:10%;text-align:justify;">
 
<div style="color:black;font-size:18px;margin-left:10%;text-align:justify;">
 
For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public.
 
For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public.
Line 188: Line 208:
 
</div>
 
</div>
  
−
<div class="mid2" style="background-color:#d0d0d0;top:170%;">
+
<div class="mid2" style="background-color:#d0d0d0;top:130%;">
 
<div style="font-size:60px;color:#140731;margin-left:35%;margin-top:2%;">
 
<div style="font-size:60px;color:#140731;margin-left:35%;margin-top:2%;">
−
Start Our Journey
+
<br>
 +
Start the Journey
 
</div>
 
</div>
 
<br></br>
 
<br></br>
 
<br></br>
 
<br></br>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:35%;position:absolute;margin-left:10%;" src="https://static.igem.org/mediawiki/2016/4/40/CGU_Taiwan--t4.jpg">
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:10%;" src="https://static.igem.org/mediawiki/2016/4/40/CGU_Taiwan--t4.jpg">
−
<h2 style="font-size:35px;color:#140731;position:absolute;left:15%;top:490px;z-index:+1;text-decoration:none;">PROJECT</h2>
+
<h2 style="font-size:35px;color:#140731;position:absolute;left:15%;top:490px;z-index:+1;text-decoration:none;">PROJECT</h2></a>
−
<a href="http://facebook.com/igemcgu"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:35%;position:absolute;margin-left:38%;" src="https://static.igem.org/mediawiki/2016/c/cd/CGU_Taiwan--macrophage.jpg">
+
<a href="http://facebook.com/igemcgu"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:38%;" src="https://static.igem.org/mediawiki/2016/c/cd/CGU_Taiwan--macrophage.jpg">
−
<h3 style="font-size:35px;color:#140731;position:absolute;left:45%;top:490px;text-decoration:none;">NEWS</h3>
+
<h3 style="font-size:35px;color:#140731;position:absolute;left:45%;top:490px;text-decoration:none;">NEWS</h3></a>
−
<a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:35%;position:absolute;margin-left:66%;" src="https://static.igem.org/mediawiki/2016/7/7c/CGU_Taiwan--HA.jpg">
+
<a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><img style="border-radius:50%;border:10px solid #140731;padding:5px;width:20%;height:25%;position:absolute;margin-left:66%;" src="https://static.igem.org/mediawiki/2016/7/7c/CGU_Taiwan--HA.jpg">
−
<h4 style="font-size:35px;color:#140731;position:absolute;left:72%;top:490px;text-decoration:none;">RESULTS</h4>
+
<h4 style="font-size:35px;color:#140731;position:absolute;left:72%;top:490px;text-decoration:none;">RESULTS</h4></a>
 
</div>
 
</div>
  
−
<div class="end" style="top:250%;">
+
<div class="end" style="top:190%;">
 
<div style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;">
 
<div style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;">
 
Chang Gung University
 
Chang Gung University
Line 211: Line 232:
 
<br>
 
<br>
 
TEL: +886-3-2118800 FAX:+886-3-2118700
 
TEL: +886-3-2118800 FAX:+886-3-2118700
−
<img src="https://static.igem.org/mediawiki/2016/d/d8/CGU_Taiwan--home3.jpg" style="position:absolute;top:0%;margin-left:25%;width:30%;height:45%;margin-top:3%;">
+
<img src="https://static.igem.org/mediawiki/2016/e/eb/CGU_Taiwan--sponsor0.6.jpg" style="position:absolute;top:0%;margin-left:25%;width:35%;height:45%;margin-top:3%;">
 
</div>
 
</div>
 
</div>
 
</div>
 
<br><br><br><br><br>
 
<br><br><br><br><br>
−
<div class="end2" style="top:300%;">
 
−
<br><br>
 
−
<b style="color:white;font-size:40px;margin-top:5%;margin-left:42%;text-decoration:none;">SITE MAP</b>
 
−
<hr style="border:0;width:90%;color:white;background-color:white;height:2px;margin-left:5%;"></hr>
 
−
<br><br><br>
 
  
 +
<div class="end2" style="top:210%;">
 +
<br>
 +
<ul class="list3" class="margin-left:1%;margin-top:2%;">
 +
<li><a href="#anchor1"><b style="color:white;font-size:28px;margin-left:7%;">TOP</a></li>
 +
</ul>
 +
<br>
 
<div class="sitemap" style="margin-left:5%;">
 
<div class="sitemap" style="margin-left:5%;">
 +
<br>
 +
<b style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</b><br>
 +
<br><br>
 +
<img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:50%;height:90%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg">
 +
</div>
 +
 +
<div class="sitemap" style="margin-left:22%;margin-top:-1%;">
 
<ul class="list" class="margin-left:5%;">
 
<ul class="list" class="margin-left:5%;">
−
<li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li>
+
<li><a href="https://2016.igem.org/Team:CGU_Taiwan"><b style="color:white;font-size:18px;margin-left:20%;">HOME</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><b style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><b style="color:white;font-size:18px;margin-left:20%;">INTERLAB</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><b style="color:white;font-size:18px;margin-left:20%;">SAFETY</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><b style="color:white;font-size:18px;margin-left:20%;">PARTS</li></a>
 +
</ul>
 +
</div>
 +
 
 +
<div class="sitemap" style="margin-left:40%;margin-top:-2%;">
 +
<ul class="list" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description"><b style="color:white;font-size:18px;margin-left:20%;">PROJECT</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Design"><b style="color:white;font-size:17px;margin-left:10%;">Design</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Background"><b style="color:white;font-size:17px;margin-left:10%;">Background</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Results"><b style="color:white;font-size:17px;margin-left:10%;">Results</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><b style="color:white;font-size:17px;margin-left:10%;">Proof</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><b style="color:white;font-size:17px;margin-left:10%;">Notebook</li></a>
 
<br><br>
 
<br><br>
 
</ul>
 
</ul>
−
<br>
+
</ul>
−
<img style="background-color:#0D014D;margin-left:20%;border-radius:50%;border:6px solid white;padding:5px;width:50%;height:75%;position:absolute;margin-left:2%;" src="https://static.igem.org/mediawiki/2016/0/03/CGU_Taiwan--leishmania3.jpg">
+
</div>
 +
 
 +
<div class="sitemap" style="margin-left:55%;margin-top:-3.5%;">
 +
<ul class="list" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><b style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:50%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><b style="color:white;font-size:17px;margin-left:10%;">Survey</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><b style="color:white;font-size:17px;margin-left:10%;">Education</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><b style="color:white;font-size:17px;margin-left:10%;">Communication</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><b style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</li></a>
 +
</ul>
 +
</ul>
 +
</div>
 +
 
 +
<div class="sitemap" style="margin-left:75%;margin-top:-3.5%;">
 +
<ul class="list" class="margin-left:5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software"><b style="color:white;font-size:18px;margin-left:20%;">MODELING</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;">
 +
<li><a href="http://163.25.92.36/igemcgu/igemwebhome.htm"><b style="color:white;font-size:17px;margin-left:10%;">McHug</li></a>
 +
</ul>
 +
</ul>
 +
<ul class="list" class="margin-left:1%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team"><b style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</li></a>
 +
<br><br>
 +
<ul class="list2" class="margin-left:6%;margin-top:-5%;">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><b style="color:white;font-size:17px;margin-left:10%;">Collaborations</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><b style="color:white;font-size:17px;margin-left:10%;">Attributions</li></a>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><b style="color:white;font-size:17px;margin-left:10%;">Sponsors</li></a>
 +
</ul>
 +
</ul>
 
</div>
 
</div>
  

Latest revision as of 07:04, 2 December 2016

  • HOME
  • ACHIEVEMENTS
  • PROJECT
  • MODELING
  • HUMAN PRACTICES
  • PEOPLE
  • INTERLAB
  • SAFETY
  • PARTS














    • Abstract




    Leijuvant- A Revolutionary Choice of Vaccine Helper

    For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public.



    Start the Journey




    PROJECT

    NEWS

    RESULTS
    Chang Gung University

    No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33302, Taiwan (R.O.C.)
    TEL: +886-3-2118800 FAX:+886-3-2118700








    SITE MAP